The Italian Society for Rheumatology clinical practice guidelines for rheumatoid arthritis

S. Parisi1,2, A. Bortoluzzi1,3, G.D. Sebastiani4, F. Conti5, R. Caporali6, N. Ughi1,7, I. Prevetel, A. Ariani8, M. Manara1,7, G. Carrara1, C.A. Scire1,8
1Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy; 2Rheumatology Unit, University Hospital, Turin, Italy; 3Department of Medical Sciences, Rheumatology Section, University of Ferrara, Italy; 4Rheumatology Unit, Azienda OSPedaliera San Camillo-Forlanini, Rome, Italy; 5Rheumatology Division, I Clinica Medica, Policlinico Umberto I, Rome, Italy; 6Department of Rheumatology, University and IRCCS Foundation Policlinico S. Matteo, Pavia, Italy; 7Division of Clinical Rheumatology, Centro Specializzato Ortopedico-Traumatologico Gaetano Pini CTO ASST, Milan, Italy; 8Department of Medicine, Internal Medicine and Rheumatology Unit, Azienda Ospedaliero-Università Parma, Italy

SUMMARY
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder characterised by chronic joint inflammation, leading to functional disability and increased risk of premature death. Clinical practice guidelines (CPGs) are expected to play a key role in improving management of RA, across the different phases of the disease course. Since new evidence has become available, the Italian Society for Rheumatology (SIR) has been prompted to update the 2011 recommendations on management of RA. The framework of the Guidelines International Network Adaptation Working Group was adopted to identify, appraise (AGREE II), synthesize, and customize the existing RA CPGs to the Italian healthcare context. The task force consisting of rheumatologists from the SIR Epidemiology Research Unit and a committee with experience in RA identified key health questions to guide a systematic literature review. The target audience includes physicians and health professionals who manage RA in practice, and the target population includes adult patients diagnosed as having RA. An external multi-disciplinary committee rated the final version of the CPGs. From the systematic search in databases (Medline, Embase) and grey literature, 6 CPGs were selected and appraised by two independent raters. Combining evidence and statements from these CPGs and clinical expertise, 8 (Management) +6 (Safety) recommendations were developed and graded according to the level of evidence. The statements and potential impact on clinical practice were discussed and assessed. These revised recommendations are intended to provide guidance for the management of RA and to disseminate the best evidence-based clinical practices for this disease.

Key words: Clinical practice guidelines, recommendations, rheumatoid arthritis, management, safety.
developed specific recommendations aiming to stratify and minimize adverse events. In particular, the presence of comorbidities (e.g., cardiovascular disease), the concurrence of infections and host-related risk factors (e.g., hepatotropic virus hepatitis B and C), and the possible reactivation of latent tuberculosis infection, strongly affect drug choice and patient monitoring. The Italian Society for Rheumatology (SIR) issued guidelines on the management and safety of drugs for RA in 2011 (11, 12). Since their publication, new scientific evidence concerning management of RA has emerged. Updating high-quality recommendations and Clinical Practice Guidelines (CPGs) in clinical practice requires substantial consumption of time and resources and a great deal of effort to be properly adapted and disseminated in the local context. The ADAPTE methodology, based on already existing guidelines, is a valid alternative to de novo local CPG development (13, 14), and it is expected to play a key role in improving management of patients with RA.

**NEED FOR ITALIAN GUIDANCE**

The most recent SIR recommendations focusing on the management and safety of patients with RA were published in 2011 (11, 12) and aimed to update EULAR 2010 (15). The increase in standards of care has made management of RA more and more complex. Therefore, recommendations on management of patients with RA are needed to provide physicians, patients, financial backers, regulators and other healthcare suppliers with evidence-based guidance supported by the views of experts. The evidence in terms of efficacy and safety for available drugs has accumulated and new treatment options are available. Finally, several new international guidelines on RA have been published over the last few years (16, 17).

**Objective**

These CPGs aim to offer revised, evidence-based, and adapted recommendations for the management and safety of patients with RA in Italy.

**Target patient population**

Adult patients (age ≥18 years) with clinical diagnosis of RA.

**Target users**

Attending physicians (general practitioners, rheumatologists) and health professionals who manage patients with RA in primary care, and hospital and community practice settings. Patients, policy makers and those responsible for commissioning care for patients with RA in the Italian National Health Service (NHS).

**What is covered**

These CPGs focus on holistic management of patients with RA.

**Areas that are not covered**

Recommendations on surgical management and post-operative rehabilitation of patients with RA are not included in these guidelines.

**MATERIALS AND METHODS**

**Approach to guideline development**

De novo guideline development is time-consuming and requires substantial costs (funds, expertise, and human resources). As several RA guidelines have been published by international scientific associations, a systematic approach based on the framework of the Guidelines International Network Adaptation Working Group (http://www.g-i-n.net) following the work of the ADAPTE collaboration (13, 14) has been adopted to identify, appraise, synthesize, and customize the existing international guidelines to the needs of the Italian healthcare context.

**Assembly of the Working Group**

The Working Group included 10 rheumatologists on behalf of the SIR. Six rheumatologists (N.U., I.P., M.M., A.B, A.A., S.P.), one biostatistician (G.C.) and a project coordinator (C.A.S.) from the SIR Epidemiology Research Unit were responsible for the methodology of development of these CPGs. Three expert clinicians designated by SIR (F.C., R.C.,
G.D.S.) were engaged in each phase of the guideline development by attending a meeting at the 54th SIR National Meeting (November, 22nd-25th 2017), contributing to e-mail discussions, and participating in web-meetings (April, 30th and July 10th 2018).

Stakeholder involvement
The draft of these recommendations has been revised and rated by an external multidisciplinary commission of rheumatologists, a general practitioner, and a representative of patients’ associations at the invitation of SIR. The recommendations were developed without any input from, or cooperation with, any pharmaceutical company.

Defining the scope
A comprehensive list of potential management questions to be addressed was developed a priori and defined by consensus. 16 health questions (9 about management and 7 about safety) were identified (Table I) and guided the systematic literature searches.

Inclusion and exclusion criteria
International CPGs and consensus statements with recommendations for RA endorsed by scientific societies such as SIR, The Italian group for the Study and Management of the Infections in patients with Rheumatic diseases (ISIMIR), the American College of Rheumatology (ACR), the European League Against Rheumatism (EULAR), published

Table I - Key questions regarding the overall management and safety of RA patients.

<table>
<thead>
<tr>
<th>No.</th>
<th>Text of the health question</th>
<th>No. recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MANAGEMENT QUESTIONS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>When to start therapy for RA?</td>
<td>I</td>
</tr>
<tr>
<td>2.</td>
<td>What is the initial therapy for the treatment of RA?</td>
<td>II</td>
</tr>
<tr>
<td>3.</td>
<td>What is the role of glucocorticoid therapy?</td>
<td>III</td>
</tr>
<tr>
<td>4.</td>
<td>In case of intolerance or contraindications to the MTX, are there any preferences for another csDMARDs or bDMARDs?</td>
<td>IV</td>
</tr>
<tr>
<td>5.</td>
<td>After how long is it correct to judge the therapy non-optimal (not in remission or in LDA) and which parameters should be used?</td>
<td>NA</td>
</tr>
<tr>
<td>6.</td>
<td>What pharmacological treatment after csDMARDs failure?</td>
<td>V</td>
</tr>
<tr>
<td>7.</td>
<td>After failure of the first bDMARD, which strategy is preferable? switch or swap?</td>
<td>VI</td>
</tr>
<tr>
<td>8.</td>
<td>After failure of the second or subsequent bDMARD, which strategy is preferable? switch or swap?</td>
<td>VII</td>
</tr>
<tr>
<td>9.</td>
<td>In case of persistent remission, is it possible to reduce or discontinue therapy with bDMARDs and csDMARDs?</td>
<td>VIII</td>
</tr>
<tr>
<td><strong>SAFETY QUESTIONS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>TB: request IGRA and/or TST + RX Chest before starting therapy with bDMARDs, or only IGRA and proceed with other tests based on the results? Re-check? If so, with what timing?</td>
<td>I</td>
</tr>
<tr>
<td>2.</td>
<td>Hepatitis B: when to start prophylaxis and with which medication? For how long? When to suspend it? Which are the indicators for monitoring and which for timing?</td>
<td>II</td>
</tr>
<tr>
<td>3.</td>
<td>Hepatitis C: which patients can be treated with the new therapies available? When to start treatment? Which are the indicators for monitoring and which for timing?</td>
<td>III</td>
</tr>
<tr>
<td>4.</td>
<td>CVD: Which strategy to adopt in case of cardiovascular disease?</td>
<td>IV</td>
</tr>
<tr>
<td>5.</td>
<td>Which therapeutic strategy to use in patients with previous neoplasia?</td>
<td>V</td>
</tr>
<tr>
<td>6.</td>
<td>What are indications and contraindications to vaccinations in patients with RA?</td>
<td>VI</td>
</tr>
<tr>
<td>7.</td>
<td>Which strategy to adopt in case of pregnancy during RA?</td>
<td>NA</td>
</tr>
</tbody>
</table>

RA, rheumatoid arthritis; TB, tuberculosis; MTX, methotrexate; csDMARD, conventional synthetic disease-modifying antirheumatic drug; bDMARD, biologic disease-modifying antirheumatic drug; LDA, low disease activity; TST, tuberculosis skin test; IGRA, interferon gamma release assay; CVD, cardiovascular disease; NA, not answered.
in English or Italian between January 1st, 2012, and July 31st 2017, were included. Non-international recommendations were considered only if the role of the scientific society was judged relevant. Reasons for exclusion: study design [randomized controlled trials (RCT) and uncontrolled trials, observational studies, editorials, commentaries, conference abstracts and narrative/systematic reviews]; languages other than English and Italian; poor methodology and reporting; non-original CPGs (i.e. duplication, adaptation or update of previous recommendations) and those not covering any key health questions.

Search strategy
The strategy was discussed with a member of the SIR Epidemiology Research Unit and the systematic literature search was performed by S.P. in Medline and Embase databases combining keywords for rheumatoid arthritis, guidelines and consensus statements. Furthermore, a grey literature search of rheumatology societies, guideline clearinghouses, cross-references and a gate-keeper (Google Scholar) was performed (Appendix 1). All search results were screened by 2 independent reviewers (S.P., A.B.), and disagreements were resolved by consensus. A flow chart of the results is shown in Figure 1.

Appraisal of guideline quality
Guideline quality was assessed by two trained raters (S.P., A.B.) using the online Appraisal of Guidelines Research and Evaluation (AGREE) II instrument (18). The AGREE II is made up of 23 items organized into 6 quality domains: scope and purpose, stakeholder involvement, rigor of development, clarity of presentation, applicability, and editorial independence. Upon completing the 23 items, the criteria considered in the assessment process were used to formulate a score and a single-item overall assessment of the guideline as Recommend (R), Recommend with Provisos (R*), or Would Not Recommend. The AGREE assessments were not considered as criteria for exclusion.

Level of evidence and strength of recommendation
Different grading systems for evidence were used across the CPGs. In order to harmonize these differences, each guideline’s grading system was revised and reported rating the level of evidence and strength of recommendation by the Oxford Levels of Evidence (19) (Table II). In case of disagreements, the rating of the recommendation based on the most updated evidence base was considered.

Evidence framework and development of recommendations
The descriptive characteristics of included CPGs (guideline developer, topic, country, language, publication year, end-of-search date, grading system) and AGREE scores were synthesized. For each key question, evidence tables containing guideline characteristics, recommendations, AGREE summary scores, and level of evidence and strength of recommendation according to the original grading system were prepared. Each recommendation was developed by endorsement or adaptation and reword-
External review
The draft of the recommendations was sent to external reviewers (n=14) for comment and rating. An online survey was performed via Google Forms between October and November 2018 and feedback from respondents (n=10, response rate 71.4%) was considered to finalize the recommendations. The results of the external review are provided as supplementary material (Appendix 2).

RESULTS
Key to understanding these guidelines
Each recommendation is presented with a level of evidence and strength and is accompanied by supporting text that is structured as follows:

Overarching Principles. Presentation of general principles for the treatment of patients with RA as overarching.
Recommendation. The final statement of SIR.
Summary of guidelines. A synthesis of recommendations made by RA guidelines identified from the systematic review.
Recommendation/supporting evidence. Specific source guidelines that were used for adaptation.
Evidence for recommendation. Results of the panel discussion of the adapted recommendation with regard to further specifications and comments on the sources used to develop the recommendation.

Overarching principles
The aim of the RA treatment should be the best care of the patient. It must be based on a shared decision between the patient and the rheumatologist who is the specialist who should primarily care for patients with RA. This principle remained confirmed also in these guidelines. The target of clinicians is remission or low disease activity, with long-lasting effect and with as little pharmacological treatment as possible. Thus, prognostic factors (Table III), further to disease du-
ration, should be importantly taken into account (21).

Treatment decisions should be guided by disease activity as well as by comorbidities and safety issues. It is suggested that disease activity be categorized as low, moderate, or high as per validated scales based on the indices reported in Tables IV and V.

**Recommendations**

6 original CPGs (16, 17, 22-25) were selected and used to accomplish the final first set of 8 recommendations on management (Table VI) and the second set of 6 recommendations on safety (Table VII). An algorithm which summarizes the pathway for the treatment strategy of patients with RA is shown in Figure 2. Glossary and definitions are presented in Appendix 3.

**FIRST SET MANAGEMENT**

**RECOMMENDATION 1**

Treatment with csDMARDs should be started as soon as the diagnosis of RA is made. (1, A).

*(Level 1; Strength A)*

*Summary of guidelines.* The search identified 2 CPGs that addressed the optimal management of RA. Both CPGs recommend clinicians to start therapy with csDMARDs as soon as possible in RA.

*Recommendation/supporting evidence.* EULAR 2016 (16) and ACR 2015 (17).

*Evidence for recommendation.* The panel agreed upon the importance of early treatment at diagnosis. It is now widely recognized that early treatment enables prevention of damage to most patients with RA (26).

**RECOMMENDATION 2**

MTX should be part of the first treatment strategy. (1, A).

*(Level 1; Strength A)*

*Summary of guidelines.* The search identified 2 CPGs that addressed the optimal management of RA. According to EULAR and ACR recommendations, clinicians should start therapy with MTX as soon as the diagnosis of RA is defined.

*Recommendation/supporting evidence.* EULAR 2016 (16) and ACR 2015 (17).

*Evidence for recommendation.* The panel agreed upon the role of MTX as the first treatment strategy at diagnosis. MTX continues to be the anchor drug for RA patients both in monotherapy and in combination with other drugs. Furthermore, robust data indicate that MTX has a positive impact on morbidity and mortality in RA (27, 28).

**RECOMMENDATION 3**

A short-term course of glucocorticoids can be considered to control active RA in combination with csDMARDs. In view of their cumulative side effects, they should be used at the lowest dose necessary and tapered as rapidly as clinically feasible (<6 months).

*Summary of guidelines.* The search identified 2 CPGs that addressed the optimal management of RA. Both CPGs recommend clinicians to start therapy with csDMARDs as soon as possible in RA.

*Recommendation/supporting evidence.* EULAR 2016 (16) and ACR 2015 (17).

*Evidence for recommendation.* The panel agreed upon the importance of early treatment at diagnosis. It is now widely recognized that early treatment enables prevention of damage to most patients with RA (26).

---

**Table V - Disease Activity Index Range (Adapted from Ref. 166).**

<table>
<thead>
<tr>
<th>Reference Values</th>
<th>DAS28 (ESR)</th>
<th>SDAI</th>
<th>CDAI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Remission</strong></td>
<td>&lt;2.6</td>
<td>≤3.3</td>
<td>≤2.8</td>
</tr>
<tr>
<td><strong>Low</strong></td>
<td>≥2.6 e &lt;3.2</td>
<td>≥3.4 e ≤11</td>
<td>&gt;2.8 e ≤10</td>
</tr>
<tr>
<td><strong>Moderate</strong></td>
<td>≥3.2 e ≤5.1</td>
<td>&gt;11 e ≤26</td>
<td>&gt;10 e ≤22</td>
</tr>
<tr>
<td><strong>High</strong></td>
<td>&gt;5.1</td>
<td>&gt;26</td>
<td>&gt;22</td>
</tr>
</tbody>
</table>

DAS28, Disease Activity Score 28 joints; ESR, Erythrocyte sedimentation rate; SDAI, Simplified Disease Activity Index; CDAI, Clinical Disease Activity Index.
Summary of guidelines. The search identified 2 CPGs that addressed optimal management of GC in RA. According to the EULAR recommendations, clinicians should use glucocorticoids when initiating or switching csDMARDs, in different dose regimens and routes of administration, but they should be tapered as rapidly as clinically feasible, considering the long-term side effects.

**Recommendation/supporting evidence.** EULAR 2016 (16), EULAR early 2016 (22).

**Evidence for recommendation.** The panel agreed with the concept of short-term instead of low-dose. Moreover, intra-articular steroids may be considered to improve joint symptoms (in association with DMARDs) especially in patients with early arthritis (29).

**RECOMMENDATION 4**

In patients with a contraindication or intolerance to MTX, leflunomide or sulfasalazine should be considered as part of the (first) treatment strategy. (1, A). (Level 1; Strength A)

**Summary of guidelines.** The search identified 1 CPG that addressed optimal management of csDMARDs in RA.

**Recommendation/supporting evidence.** EULAR 2016 (16).

**Evidence for recommendation.** According to EULAR 2016, clinicians should start therapy with leflunomide (LFN) or Sulfasalazine (SSZ) in selected RA patients, since they have proved to be efficacious (30, 31). As for MTX, also in this treatment strategy the panel means the use of LFN and SSZ in monotherapy or in combination with other bDMARDs (32-35). Compared to the other csDMARDs, hydroxychloroquine, although still used, especially in the forms of mild RA, does not delay the articular damage, therefore it has not been included (36).

**RECOMMENDATION 5**

- If the treatment target is not achieved with a csDMARD strategy, in the absence of poor prognostic factors, other csDMARDs should be considered.*
- If the treatment target is not achieved with the first csDMARD strategy, when poor prognostic factors are present, addition of a bDMARD† or a tsDMARD should be considered (add a TNF-i or a non-TNF-i or JAK-i without any order of preference).*

*(5, D); †(1, A). (Level 1-5; Strength A-D)

**Summary of guidelines.** The search identified 2 CPGs that addressed optimal management of DMARDs in RA. According to ACR and EULAR, clinicians should add another csDMARD in the absence of poor prognostic factors. On the other hand, clinicians should consider adding bDMARD or tsDMARD when poor prognostic factors are present (Table III).

**Recommendation/supporting evidence.** EULAR 2016 (16), ACR 2015 (17).

**Evidence for recommendation.** The panel agreed not to indicate any hierarchical position in the bDMARDs or tsDMARDs (16, 37-39). Considering the availability of biosimilars, these should be preferred to originators for cost reasons (16, 40-42). Furthermore, the panel decided to include the tsDMARDs (Janus Kinase inhibitors, JAK-i) in this recommendation following trials on the efficacy and safety of tofacitinib and baricitinib, both already approved in Italy (43). With patients who cannot use csDMARDs as comedication, IL-6 pathway inhibitors and tsDMARDs (Baricitinib) may have some advantage compared with other bDMARDs. However, the panel preferred not to recommend it due to the lack of consistent evidence (44-46).

**RECOMMENDATION 6**

If a bDMARD has failed, treatment with another bDMARD or a tsDMARD should be considered; if one TNF-i therapy has failed, patients may receive another TNF-i or an agent with another mode of action. (5, D). (Level 5; Strength D)
Summary of guidelines. The search identified 2 CPGs that addressed optimal management of bDMARDs in RA. One CPG (17) recommended changing the mechanism of action upon failure of TNF-inhibitors (TNF-i), while the other recommended the change of therapy irrespective of the mechanism of action (16).

Recommendation/supporting evidence. EULAR 2016 (16), ACR 2015 (17)

Evidence for recommendation. Clinicians should consider another bDMARD or tsDMARD when the first bDMARD has failed without any preference between TNF-i or other mechanism of action. The panel agreed upon the importance of considering another strategy with bDMARD or tsDMARD when the first treatment has failed according to a cycling or switch strategy. The panel preferred this solution considering prospective studies and meta-analysis which showed no differences between the two approaches (47-49).

RECOMMENDATION 7

Patients who fail to achieve remission or low disease activity with a second bDMARD therapy are recommended to switch to another bDMARD or a tsDMARD. If

Table VI - Final set of Recommendations on treatment strategy in RA (Management).

<table>
<thead>
<tr>
<th>No.</th>
<th>The final set of “Management” Recommendations</th>
<th>Category of Evidence</th>
<th>Grade of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Treatment with csDMARDs should be started as soon as the diagnosis of RA is made.</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>2</td>
<td>MTX should be part of the first treatment strategy.</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>3</td>
<td>Short-term course of glucocorticoids can be considered to control active RA in combination with csDMARDs. In view of their cumulative side effects, they should be used at the lowest dose necessary and tapered as rapidly as clinically feasible (&lt;6 months). Intra-articular glucocorticoid injections should be considered for the relief of local symptoms of inflammation.</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>4</td>
<td>In patients with a contraindication or intolerance to MTX, LFN or SSZ should be considered as part of the (first) treatment strategy.</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>5</td>
<td>If the treatment target is not achieved with a csDMARD strategy, in the absence of poor prognostic factors, other csDMARDs should be considered. If the treatment target is not achieved with the first csDMARD strategy, when poor prognostic factors are present; addition of a bDMARD or a tsDMARD should be considered (add a TNF-i or a non-TNF-i or JAK-i without any particular order of preference).</td>
<td>5*</td>
<td>D*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1*</td>
<td>A*</td>
</tr>
<tr>
<td>6</td>
<td>If a bDMARD has failed, treatment with another bDMARD or a tsDMARD should be considered; if one TNF-i therapy has failed, patients may receive another TNF-i or an agent with another mode of action.</td>
<td>5</td>
<td>D</td>
</tr>
<tr>
<td>7</td>
<td>Patients who fail to achieve remission or low disease activity with a second bDMARD therapy are recommended to switch to another bDMARD agent or a tsDMARD. If the second bDMARD failure is TNF-i: use another bDMARD (non-TNF-i) or a tsDMARD with or without MTX.</td>
<td>5</td>
<td>D</td>
</tr>
<tr>
<td>8</td>
<td>If a patient is in sustained remission, a reduction in treatment should be considered. - bDMARDs or tsDMARDs tapering, especially if this treatment is combined with a csDMARDs, could be considered. - csDMARDs tapering could be considered.</td>
<td>2*</td>
<td>B*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4*</td>
<td>C*</td>
</tr>
</tbody>
</table>

RA, Rheumatoid Arthritis; MTX, Methotrexate; LFN, Leflunomide; SSZ, sulfasalazine; csDMARD, conventional synthetic disease-modifying antirheumatic drug; bDMARD, biologic disease-modifying antirheumatic drug; tsDMARD, target synthetic disease-modifying antirheumatic drug; TNF-i, Tumor Necrosis Factor inhibitor; JAK-i, janus kinase inhibitor.

The symbols (*, †) relate to the corresponding symbols in the recommendations, showing in the respective grade.
the second bDMARD failure is TNF-i: use another bDMARD (non-TNF-i) or a tsDMARD with or without MTX. (5, D).

Summary of guidelines. The search identified 2 CPGs that addressed optimal management of bDMARDs failure in RA. According to ACR and EULAR recommendations, clinicians should consider another bDMARD or tsDMARD when another bDMARD has failed, preferring another mechanism of action (non-TNF-i or tsDMARD).

Recommendation/supporting evidence. EU-LAR 2016 (16), ACR 2015 (17)

Evidence for recommendation. The panel agreed upon the importance of achieving remission without glucocorticoid, because it is fundamental to take into consideration the tapering of the treatment (bDMARD, tsDMARD and csDMARD). Tapering is understood as reduction of the dose or extension of interval between drug administrations (i.e. spacing). The panel also agreed that the recommendation implies tapering until possible interruption of the bDMARD first, if in combination with the csDMARD; tapering of csDMARDs should be considered after the withdrawal of the bDMARD; on the other hand, tapering and stopping bDMARD monotherapy has not yet been studied.

SECOND SET

SAFETY TUBERCULOSIS (TB)

RECOMMENDATION 1

Screening for active TB or Latent TB is recommended prior to starting bDMARD or tsDMARD therapy. Initial Tuberculosis Skin Test (TST) or Interferon Gamma Release Assay (IGRA) is recommended. IGRA is preferred if the patient has a history of Bacillus Calmette-Guérin (BCG) vaccination.*

a) Patients with a positive initial or repeat TST or IGRA should have a chest radiograph and, if positive for past TB exposure or active TB, a subsequent sputum examination to check for the presence of active TB.*

b) Patients with a negative screening TST or IGRA may not need further workup in the absence of risk factors and/or clinical suspicion for TB.*

c) If the RA patient has active or latent TB based on the test results the panel recommends appropriate anti-tubercular treatment and consideration for referral to a specialist.†

d) Treatment with tsDMARDs or bDMARDs can be initiated or resumed after 1 month of latent TB treatment with anti-tubercular medications and after completion of the treatment of active TB, if applicable according to the refer-
ence specialist (pulmonologist or infectious disease specialist).*

e) Annual testing is recommended in RA patients who live, travel or work in situations where TB exposure is likely while they continue treatment with bDMARDs or tsDMARDs.*

**Risk factors for TB exposure:** close contacts of persons known or suspected to have active tuberculosis; foreign born persons from areas that have a high incidence of active TB (e.g. Africa, Asia, Eastern Europe, Latin America, and Russia); persons who visit areas with a high prevalence of active TB (especially if visits are frequent or prolonged); residents and employees of congregate settings whose clients are at increased risk for active TB.

* (2,C) †(2,B) (Level 2; Strength B-C)

**Summary of guidelines.** The search identified 2 CPGs that addressed optimal screening and monitoring for active or latent TB in RA patients. The ACR 2015 guidelines modified the ACR 2012 by including tofacitinib in the screening.

**Recommendation/supporting evidence.** ACR 2015 (17), ACR 2012 (24).

**Evidence for recommendation.** The Panel, according to the ACR 2012 and 2015 Guidelines, recommends screening to identify latent or active tuberculosis infection in all RA patients being considered for therapy with bDMARDs and tsDMARDs, regardless of the presence of risk factors (55). Since patients with RA may have false-negative tuberculin skin test (TST) or interferon gamma release assay (IGRA) results due to immunosuppression, a negative TST or IGRA should not be interpreted as excluding the possibility that patient has LTBI. Patients who test positive for TST or IGRA at baseline are expected to remain positive for these tests even after successful treatment of active or latent TB. These patient need monitoring for clinical signs and symptoms of recurrent TB, since repeating tests will not help in diagnosis of recurrent TB. In immunosuppressed RA patients with risk factors for TB and negative initial screening tests, a repeat TST or IGRA could be considered 1-3 weeks after the initial negative screening.

The Panel indicated that in the absence of significant new knowledge, development of an alternate recommendation was not warranted with one exception, that the same TB screening algorithm as described for bDMARDs should be followed for patients receiving tsDMARDs. (56, 57).

Data from clinical trials seem to indicate increased risk of TB reactivation in patients treated with TNF-i agents with respect to non-TNF-i. This seems to confirm the class effect resulting from TNF inhibition, which leads to impaired TB granuloma formation (58). The Panel therefore recommends individualizing the choice of therapy in accordance with the respective drug-related risk (59). The data for Italy come from the TB notification system of the Ministry of Health and constitute the official information flow, which is referred to for monitoring the progress of the disease in Italy. The current epidemiological situation of TB in Italy is characterized by a low incidence in the general population, and by the concentration of cases in some groups at risk and in some age groups. In fact, since 2009 there has been a steady increase in the proportion of cases notified among citizens born abroad (44% in 2005 and 66% in 2014) (60). The most recent data relating to Italy are published in the joint ECDC document and WHO Europe “Tuberculosis surveillance and monitoring in Europe 2018” and confirm that Italy is one of the countries with low disease incidence (<20/100,000) (60). After completion of the treatment of active TB, treatment with bDMARDs or tsDMARDs can be initiated or resumed and the panel suggests that a joint decision with the reference pulmonologist or infectious disease specialist should be taken.

**RECOMMENDATION 2**

**HBV infection**

a) All RA patients should be screened for HBsAg, antiHBsAb and antiHBcAb, especially before starting bDMARDs or tsDMARDs.*

b) AntiHBcAb positive and HBsAg negative patients should undergo further evaluations, including HBV DNA and
liver function tests, before starting immunosuppressive therapy. RA treatment should be the same as that of unexposed patients, as long as the patient’s viral load is monitored regularly, every 6-12 months.*

c) HBsAg positive patients should undergo further assessments, including quantitative HBsAg, HBeAg, anti HBe, HBV DNA and anti HDV IgG and liver function tests, before starting immunosuppressive therapy.†

d) Active HBV carriers should be referred to the specialist to receive treatment with entecavir or tenofovir, in accordance with the international guidelines, before starting immunosuppressive therapy.‡

e) Acute HBV infection occurring in patients with RA, such as asymptomatic infections occurring in patients previously negative for HBV serology, should receive antiviral treatment according to international guidelines.†

f) In inactive HBV carriers, prophylaxis should be started 4 weeks before the immunosuppressive therapy and continued for 12 months after its discontinuation (24 months in the case of patients treated with rituximab).*

g) Patients stopping prophylaxis should be closely monitored.‡

*(2, B). †(1, A). ‡(5, C). (Level 1-5; Strength A-C)

Summary of guidelines. The search identified 2 CPGs that addressed optimal screening and monitoring of HBV in RA patients. Both guidelines emphasize the importance of screening for the diagnosis of RA and of paying special attention to monitoring of HBV carriers.


Evidence for recommendation. ACR 2015 guidelines suggest that immunosuppressive therapy can be safely administered when prophylactic antiviral therapy is concomitantly prescribed (61, 62). This recommendation is strong despite very low evidence (61-68). The panel supported the view that the reactivation of HBV infection needs to be carefully considered in RA patients on immunosuppressive therapy, though it is relatively infrequently reported (69, 70). A serological screening for HBV at the time of diagnosis of RA is now universally accepted and strongly recommended (71). Furthermore, no significant differences in the risk of reactivation of overt or occult HBV infections was found among the different bDMARDs, except for rituximab, which presents a higher risk. Thus, an RA patient with natural immunity from prior exposure to HBV infection (i.e., hepatitis B core [HBcAb] antibody positive and hepatitis B surface [HBsAb] antibody positive and HBs antigen [HBsAg] negative), should undergo further evaluations, including HBV DNA and liver function tests (AST, ALT, bilirubin, GGT, albumin, creatinine, INR and a complete cell blood count). In these patients the RA treatment should not be different than with unexposed patients, provided that the viral load is monitored every 6-12 months (72, 73). Even in HBsAg positive patients it is necessary to investigate further, both for the infection (quantitative HBsAg, HBeAg, anti HBe, HBV DNA and anti HDV IgG), and for the liver function (AST, ALT, bilirubin, GGT, albumin, creatinine, INR and a complete cell blood count) (71-73). For patients with chronic HBV infection who are untreated, referral for antiviral therapy is appropriate prior to immunosuppressive therapy (64, 74-80).

There are no indications for starting antiviral treatment in occult HBV carriers who are candidates for bDMARDs or tsDMARDs, except for rituximab, where antiviral treatment is suggested (25). The frequency of monitoring HBV DNA levels, in patients not receiving antiviral prophylaxis, can range from one to three months depending on the type of immunosuppressive therapy administered (e.g. combination with csDMARDs or glucocorticoids) (81-84).

RECOMMENDATION 3

HCV infection

a) All RA patients should be screened for HCV infection, especially before starting bDMARDs or tsDMARDs*.
b) RA patients with HCV infection should undergo gastroenterological / infectious evaluation for any anti-viral eradicative therapy and should not be treated differently from patients with RA without HCV infection.† *(2, B) †(5, D); (Level 2-5; Strength B-D)

Summary of guidelines. The search identified 1 CPG that addressed optimal screening and monitoring of HCV infection in RA patients. The evidence for this recommendation is very low and based on 2 RCT and small observational studies (85-96), although there is no correlation between TNF-I or MTX therapy and increased viral load in RA patients not treated with anti-viral therapy (91).

Recommendation/supporting evidence. ACR 2015 (17).

Evidence for recommendation. The panel recommended that rheumatologists collaborate with gastroenterologists and infectious disease specialists to monitor these patients. HCV RNA levels may increase during immunosuppressive therapies, but without clinically significant hepatitis (97). Immunosuppressive therapies do not seem to have a detrimental effect on the course of HCV infection. This is important considering the recent availability of highly effective anti-viral therapy for HCV (Direct Acting Antiviral drugs), the experience of which in RA is still limited (98).

RECOMMENDATION 4

Cardiovascular disease (CVD)

a) CVD risk assessment is recommended for all patients with RA at least once every 5 years and should be reconsidered following major changes in antirheumatic therapy. CVD risk estimation for patients with RA should be performed according to national guidelines and the SCORE CVD risk prediction model should be used if no national guideline is available.* *(4, D) †(3, C). ‡(2, A). (Level 2-4; Strength A-D)

b) CVD risk prediction models should be adapted for patients with RA by a 1.5 multiplication factor, if this is not already included in the model.*

c) Screening for asymptomatic atherosclerotic plaques by use of carotid ultrasound may be considered as part of the CVD risk evaluation in patients with RA.*

d) Lifestyle recommendations should emphasize the benefits of a healthy diet, regular exercise and giving up smoking for all patients.†

e) In CVD risk management, antihypertensives and statins may be used as in the general population.*

f) Prescription of Non Steroidal Anti Inflammatory Drugs (NSAIDs) in RA should be made with caution, especially for patients with documented CVD or in the presence of CVD risk factors.†

g) In case of Congestive Heart Failure: use combinations of csDMARDs or non TNF-i or tsDMARDs rather than TNF-i.†

h) Congestive Heart Failure worsening on current TNF-i therapy: use combinations of csDMARDs or non TNF-i or tsDMARDs rather than TNF-i.*

i) A TNF-i should only be used if there are no other reasonable options, and then, perhaps, only in compensated heart failure.*

Summary of guidelines. The search identified 2 CPGs that addressed optimal management of RA with Cardiovascular Diseases (CVD). According to the EULAR recommendations, in order to optimize treatment for patients with RA and CV risk, an accurate CV assessment is required. Evaluation of CV risk in RA patients should be assured once every 5 years if the risk varies from low to moderate (99), or more often for patients with intermediate to high risk, although the Systematic Coronary Risk Evaluation (SCORE) (100) has not yet been validated in AR. The risk prediction models available for the general population have been shown to underestimate CV risk in patients with RA (101), so many attempts have been made to produce RA-specific risk calculators (101, 102). Otherwise, correction factors were suggested (99, 102, 103). The addition of a multiplication factor of 1.5 to the scoring system in patients with RA was approved by EULAR for implementation in
daily clinical practice. The correction must be applied regardless of the criteria related to the disease, although high activity and duration of the disease, the presence of rheumatoid factor (RF) and/or anticitrullinated protein antibodies (ACPA) and extra-articular manifestations deserve attention (104, 105). The 2015 ACR guidelines state that the use of TNF-i is allowed in patients with CV comorbidities, but the evidence for recommendation is of very low quality. In the case of heart failure of the New York Heart Association (NYHA) III/IV class, such drugs are to be used with caution due to the risk of worsening heart failure (106, 107). The long-term use of non-selective NSAIDs/COX2 Inhibitors (COXIBs) has been associated with an increased risk of CV (108). Diclofenac is contraindicated in patients with CVD documented and recently some data support similar restrictions for the use of ibuprofen (109, 110). Naproxen seems to have the safest CVD risk profile (108, 111).

**RECOMMENDATION 5**

**Malignancy**

If the disease is moderately or highly active in the setting of a low-grade melanoma or non-melanoma skin cancer that had been previously treated, bDMARDs/tsDMARDs would be an acceptable option with close skin surveillance in conjunction with a dermatologist.*

a) In general
- use csDMARDs rather than tsDMARDs or bDMARDs.*

b) Previously treated lymphoproliferative disorders:
- use Rituximab over TNF-i†
- use combinations of csDMARDs or Abatacept or Tocilizumab rather than TNF-i.*

c) Previously treated solid organ malignancy
- same recommendations as in patients without this condition (in the absence of active malignancy, according to the reference specialist).*

*{(5, D) †(5, C) (Level 5; Strength C-D)}

**Summary of guidelines.** The search identified 1 CPG that addressed optimal management of RA patients and malignancy. ACR 2015 CPGs considered csDMARDs less immunosuppressive than bDMARDs and tsDMARDs. The recommendation concerning melanoma and non-melanoma skin cancer is conditional for the very low-quality of the evidence based on clinical experience and the paucity of retrospective studies (123, 124). The ACR 2015 recommendation concerning previously treated lymphoproliferative disorders is strongly in favor of rituximab despite very low quality evidence, since rituximab is an approved treatment for some of these disorders. On the other hand, several clinical trial data suggest that there is an increased risk of lymphoma in patients treated with TNF-i, but not with combinations of csDMARDs, abatacept or tocilizumab (124, 125).

**Evidence for recommendation.** Though bDMARDs/tsDMARDs are not the first
option, the panel indicated that, if RA disease activity is moderate or high in the context of a low-grade melanoma or non-melanoma skin cancer, bDMARDs/tsDMARDs would be an acceptable option with close skin surveillance in conjunction with a dermatologist. Moreover, a recent large European collaborative project did not confirm an overall increased risk of melanoma following exposure to TNF-α (126).

Another important point to emphasize is that immunotherapy has dramatically transformed the prognosis of several cancers (e.g. metastatic melanoma and non-small cell lung cancer). Ipilimumab, an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), has been approved by the US Food and Drug Administration and European Medicines Agency for treating metastatic melanoma (127, 128). CTLA-4 is a target of both autoimmunity and cancer. Drugs inhibiting this immune checkpoint have been developed for cancer (ipilimumab) and drugs activating this inhibitory signal have been developed for autoimmunity (abatacept). Even if no signal for a possible increased risk of cancer has been described with abatacept, the development of RA or other types of adverse events with immune checkpoint inhibitors therapy is an important warning to rheumatologists (129).

Long-term studies need to be continued in real-life patients receiving immunosuppressive drugs in general, to be sure there is no increased risk of cancer with time. Regarding tsDMARDs, no increased risk of malignancy has been reported with tofacitinib in RA; however, experience is limited and this risk must be evaluated in the long term with all JAK-i (130). Collaboration between rheumatologists and oncologists is crucial and could lead to better recognition and care of these patients.

**RECOMMENDATION 6**

**Vaccination**

a) Ideally administration of all vaccines, if indicated, should be undertaken at least 4 weeks before starting a tsDMARD or bDMARD.*

b) Concurrent administration of live, attenuated vaccines is an absolute contraindication for patients being treated with bDMARDs or tsDMARDs.*

c) Killed vaccines (Pneumococcal, Influenza^, Hepatitis B) are recommended, before initiating or during therapy with csDMARDs, tsDMARDs, bDMARDs, in RA patients. (*every year according to epidemiology).†

d) Recombinant Vaccine (Human Papilloma) is recommended before initiating or during therapy with csDMARDs, tsDMARDs, bDMARDs in RA patients (according to National Recommendations).* *(4, D) †(1, A). (Level 1-4; Strength A-D)

**Summary of guidelines.** The search identified 1 CPG that addressed optimal management of vaccination in RA patients. ACR 2015 guidelines support use of killed, recombinant and live attenuated vaccines before initiating therapy, but do not recommend the live attenuated vaccines (Herpes Zoster) during the therapy. All these recommendations have a low grade, except those on killed vaccines, because the evidence is of very low quality (131-145), and there is a safety warning about the use of live vaccines in patients receiving bDMARDs/tsDMARDs (132, 133).

**Recommendation/supporting evidence.** ACR 2015 (17).

**Evidence for recommendation.** The panel agreed to endorse the same recommendations. Moreover, responses to some killed vaccines may be reduced after rituximab therapy (141) and possibly after MTX therapy. In the recent study, among patients newly starting tofacitinib, the results highlight that tofacitinib can diminish pneumococcal vaccine immunogenicity to a similar extent as MTX, particularly when these two DMARDs are used concomitantly, whilst influenza responses are affected minimally (146).

Whenever possible, vaccines should be given prior to receiving therapy, and the Panel decided to consider both bDMARDs and tsDMARDs (130).
Pregnancy
In the absence of a recommendation on pregnancy in RA, the EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation by Götestam Skorpen et al., should be considered as reference (147).
Recently the European Medicines Agency has approved a modification to the data sheet and package leaflet of certolizumab pegol which makes it the first TNF-i that could be used in women suffering from chronic inflammatory diseases before and during pregnancy and breastfeeding (148).
The approval of the modification of the data sheet and the package leaflet of certolizumab pegol is based on the collected post-marketing data, the CRIB (149) and CRADLE (150) studies and on the analysis of pregnancy outcome data.

DISCUSSION
These recommendations contain substantial updates from previous SIR 2011 guidelines on RA. The ADAPTE collaboration methodology was adopted in this project and a complete CPG adapted to the national context was developed through the selected CPGs (16, 17, 22-25). A first part of the strategy was developed in the algorithm of treatment of RA and a second part was dedicated to safety. Compared to the previous SIR 2011 guidelines (11), an update was made on

Table VII - Final set of Recommendations on treatment strategy in RA (Safety).

<table>
<thead>
<tr>
<th>No.</th>
<th>The final set of “Safety” Recommendations</th>
<th>Category of Evidence</th>
<th>Grade of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>TUBERCULOSIS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
|     | Screening for TB is recommended prior to starting bDMARD or tsDMARD therapy. Initial TST or IGRA is recommended. IGRA is preferred if patient has a history of BCG vaccination.*  
  a) Patients with a positive initial or repeat TST or IGRA should have a chest radiograph and, if positive for past TB exposure or active TB, a subsequent sputum examination to check for the presence of active TB.*  
  b) Patients with a negative screening TST or IGRA may not need further workup in the absence of risk factors and/or clinical suspicion for TB.*  
  c) If the RA patient has active or latent TB based on the test results the panel recommends appropriate anti-tubercular treatment and consideration for referral to a specialist.†  
  d) Treatment with tsDMARDs or bDMARDs can be initiated or resumed after 1 month of latent TB treatment with anti-tubercular medications and after completion of the treatment of active TB, if applicable according to reference specialist (pulmonologist or infectious disease specialist).*  
  e) Annual testing is recommended in RA patients who live, travel or work in situations where TB exposure is likely while they continue treatment with biologics.* | 2*                        | C*                      |
| 2   | HBV INFECTION                            |                      |                         |
|     | a) All RA patients should be screened for HBsAg, antiHBsAb e antiHBeAb especially before starting a bDMARD or a tsDMARD.*  
  b) AntiHBeAb positive, HBsAg negative patients should undergo further evaluations, including HBV, DNA and liver function tests before starting immunosuppressive therapy. RA treatment should be the same as that for unexposed patients, as long as the patient’s viral load is monitored regularly, every 6-12 months.*  
  c) HBsAg positive patients should undergo further evaluation, including quantitative HBsAg, HBeAg, antiHBe, HBV DNA and anti HDV IgG and liver function tests, before starting immunosuppressive therapy.†  
  d) Active HBV carriers should be treated with entecavir or tenofovir in accordance with the international guidelines before starting immunosuppressive therapy.†  
  e) Acute HB occurring in patients with RA, such as asymptomatic infections occurring in patients previously negative for HBV serology, should receive antiviral treatment according to international guidelines.†  
  f) In inactive HBV carriers, prophylaxis should be started 4 weeks before the immunosuppressive therapy and continued for 12 months after its discontinuation (24 months in the case of rituximab-treated patients).*  
  g) Patients stopping prophylaxis should be closely monitored.* | 2*                        | B*                      |

36 Reumatismo S1/2019
<table>
<thead>
<tr>
<th>No.</th>
<th>The final set of “Safety” Recommendations</th>
<th>Category of Evidence</th>
<th>Grade of Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>HCV INFECTION</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) All RA patients should be screened</td>
<td>2*</td>
<td>B*</td>
</tr>
<tr>
<td></td>
<td>for HCV infections, especially before</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>starting a bDMARDs or tsDMARDs.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) RA patients with HCV infection</td>
<td>5†</td>
<td>D†</td>
</tr>
<tr>
<td></td>
<td>should undergo gastroenterological/</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>infectious evaluation for any anti-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>viral eradication therapy and should</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>not be treated differently from</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>patients with AR without HCV infection.†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>CARDIOVASCULAR DISEASE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) CVD risk assessment is recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>for all patients with RA at least</td>
<td>4*</td>
<td>D*</td>
</tr>
<tr>
<td></td>
<td>once every 5 years and should be</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>reconsidered following major changes</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>in antirheumatic therapy. CVD risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>estimation for patients with RA</td>
<td>3†</td>
<td>C†</td>
</tr>
<tr>
<td></td>
<td>should be performed according to</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>national guidelines and the SCORE</td>
<td>2†</td>
<td>A‡</td>
</tr>
<tr>
<td></td>
<td>CVD risk prediction model should be</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>used if no national guideline is</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>available.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) CVD risk prediction models should</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>be adapted for patients with RA by a</td>
<td>3†</td>
<td>C†</td>
</tr>
<tr>
<td></td>
<td>1.5 multiplication factor, if this is</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>not already included in the model.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>c) Screening for asymptomatic</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>atherosclerotic plaques by use of</td>
<td>2†</td>
<td>A‡</td>
</tr>
<tr>
<td></td>
<td>carotid ultrasound may be</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>considered as part of the CVD risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>evaluation in patients with RA.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>d) Lifestyle recommendations should</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>emphasize the benefits of a healthy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>diet, regular exercise and giving</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>up smoking for all patients.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>e) In CVD risk management,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>antihypertensives and statins may be</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>used as in the general population.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>f) Prescription of NSAIDs in RA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>should be given with caution,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>especially for patients with</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>documented CVD or in the presence of</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CVD risk factors.§</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>MALIGNANCY</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>If the disease is moderately or</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>highly active in the setting of a</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>low-grade melanoma or non-melanoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>skin cancer that had been previously</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>treated, biologics would be an</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>acceptable option with close skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>surveillance in conjunction with a</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>dermatologist.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) In general</td>
<td>5*</td>
<td>D*</td>
</tr>
<tr>
<td></td>
<td>- use csDMARDs rather than tsDMARDs</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>or bDMARDs.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Previously treated lymphoproliferative disorders:</td>
<td>5†</td>
<td>C†</td>
</tr>
<tr>
<td></td>
<td>- use Rituximab rather than TNF-i.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- use combination of csDMARDs or</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abatacept or Tocilizumab rather than</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TNF-i.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>c) Previously treated solid organ</td>
<td>2†</td>
<td>A‡</td>
</tr>
<tr>
<td></td>
<td>malignancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- same recommendations as in patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>without this condition (in the absence</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>of active malignancy, according to the</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>reference specialist).*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>VACCINATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) Ideally administration of all</td>
<td>4*</td>
<td>D*</td>
</tr>
<tr>
<td></td>
<td>vaccines, if indicated, should be</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>undertaken at least 4 weeks before</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>starting a tsDMARD or bDMARD.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>b) Concurrent administration of live,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>attenuated vaccines is an absolute</td>
<td>1†</td>
<td>A†</td>
</tr>
<tr>
<td></td>
<td>contraindication for patients being</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>treated with tsDMARDs or bDMARDs.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>c) Killed vaccines (Pneumococcal,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Influenza*, Hepatitis B are</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>recommended, before initiating or</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>during therapy with csDMARDs, tsDMARDs,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>bDMARDs, in RA patients. (*every year</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>according to epidemiology).*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>d) Recombinant Vaccine (Human Papilloma)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>is recommended before initiating or</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>during therapy with csDMARDs, tsDMARDs,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>bDMARDs in RA patients (according to</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>National Recommendations).*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RA, Rheumatoid Arthritis; TB, Tuberculosis; TST, Tuberculosis Skin Test; IGRA, Interferon Gamma Release Assay; BCG, Bacillus Calmette-Guérin; HBV, Hepatitis B Virus; HBsAb, Hepatitis B Surface antibodies; HBsAg, Hepatitis B Surface Antigen; HbCAb, Hepatitis B core anti-bodies; HBsAg, Hepatitis B envelope antigen; HDV, Hepatitis D Virus; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; GGT, Gamma Glutamyl Transferase; INR, International Normalized Ratio; CVD, Cardiovascular Disease; NSAID, Non-Steroidal Anti Inflammatory Drug; MTX, Methotrexate; LFN, Leflunomide; SSZ, sulfasalazine; csDMARD, conventional synthetic disease-modifying antirheumatic drug; bDMARD, biologic disease-modifying antirheumatic drug; tsDMARD, target synthetic disease-modifying antirheumatic drug; TNF-i, Tumor Necrosis Factor inhibitor; JAK-i, janus kinase inhibitor. The symbols (*, †, §, ‡) relate to the corresponding symbols in the recommendations, showing in the respective grade.
the drugs available, and tsDMARDs were included. The role of therapy with methotrexate is confirmed, which remains the first drug of choice in the treatment of RA. The association of a csDMARD (monotherapy) with glucocorticoids is more strongly suggested than before in terms of efficacy and safety, considering increasing evidence that this combination is not surpassed by csDMARD combinations (with glucocorticoids or with bDMARDs plus MTX) (151, 152). Moreover, the importance of prognostic factors as drivers in the therapeutic strategy is reaffirmed. Furthermore, the strategy to be adopted in case of failure of the bDMARDs has been redefined. Considering a continuously increasing spectrum of therapeutic options and new information on existing agents and therapeutic strategies, this update covers new treatment aspects and is

Figure 2 - Algorithm of treatment in RA.
RA, rheumatoid arthritis; MTX, methotrexate; csDMARD, conventional synthetic disease-modifying antirheumatic drug; bDMARD, biologic disease-modifying antirheumatic drug; tsDMARD, target synthetic disease-modifying antirheumatic drug; TNF-inhibitor, tumor necrosis factor inhibitor; JAK-i, janus kinase inhibitor.
built on strong and consistent evidence. The preferred instruments to be used when following patients were defined in accordance with EULAR and comprised composite measures, such as the CDAI, DAS28 and SDAI as well as the ACR/EULAR remission definitions (153, 154). We confirm the concept of short-term glucocorticoids, instead of low dose according to the EULAR recommendations, since various modes of application at different doses have proved to be efficacious. Moreover, the most important factors for reducing the risk of adverse events, such as CV events, infections, diabetes or hypertension (155-157), acknowledged the rapid tapering to discontinuation and a low cumulative dose of glucocorticoids (151, 158). In patients who cannot use csDMARDs as comedication, the EULAR Task Force indicated treatment inhibiting the IL-6 pathway and tsDMARDs as preferential since they may have some advantages compared with other bDMARDs. However, the studies on tocilizumab considered were only those of intravenous administration, while the drug is now widely used subcutaneously (159). For baricitinib only trial data are available (43-45). The rheumatologist is not only called into question for the therapeutic strategy based on the activity of the disease but is also responsible for the evaluation of the consequences and implications in the safety of the treatment. However, important data are still unknown. The question regarding how much time must elapse before considering a therapy non-optimal (not in remission or in LDA) and which parameters to use, could not be answered. Neither could that concerning the effect of different modes of action of antirheumatic drugs on CVD risk, especially JAK-i. The clinical trials did not address the efficacy of a TNF-i after other mechanisms of action (no-anti-TNF-i or JAK-i) or the efficacy of IL-6R as sarilumab after tocilizumab. Furthermore, there appears to be an increase in cases of Herpes Zoster and thrombosis during therapy with tsDMARDs which should be carefully monitored (160, 161-167). Some recommendations were strong despite low quality evidence and the panel provided justification for these recommendations. This indicates that more significant evidence is needed to derive strong recommendations in the future.

**Plans of update**

These recommendations were endorsed by SIR as guidelines only and they do not substitute the individual clinicians’ judgment since they may not apply to all patients and all clinical situations. The SIR plans to review and update these recommendations in the future to determine if they remain current and to capture future treatments or advances in the management of RA.

**Acknowledgements:** the Authors acknowledge all the external reviewers (in alphabetical order of those who gave consent for publication): S. Bugatti, M.S. Chimenti, S. Guiducci, F. Iannone, C. Lomater, V. Mascheroni, B. Raffeiner R. Scrivo, M. Sebastiani, S. Tonolo. We are grateful to Solazzo T. as part of the SIR secretariat for administrative support.

**Contributions:** all authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version for publication. Concept and design: C.A.S., S.P., A.B., M.M., I.P., A.A., N.U. Systematic review search and CPGs rating: S.P., A.B. Analysis and discussion of the recommendations: S.P., A.B., G.D.S., F.C., R.C., M.M., I.P., N.U., A.A., C.A.S.

**Funding:** these recommendations matched no specific funding from any bodies in the public, commercial sectors or any non-profit organization. Non-economic support, such as meeting rooms and secretariat services, was provided by SIR to carry out the work described in this manuscript.

**Disclosure statements:** S.P. reports a grant from SIR and others related to advisory boards from AbbVie, Celgene, Janssen, Biogen, Bristol-Myers Squibb, Sanofi, and others related to scientific advice from Baldacci, and Chiesi outside the submitted work; A.B. reports honoraria due to advisory board from GlaxoSmithKline outside the submitted work; F.C reports speaker
fees from Bristol-Myers Squibb, AbbVie, Pfizer, Lilly and Merck Sharp & Dohme; R. C. reports speaker fees related to advisory boards from Abbvie, Bristol Myers Squibb, Celgene, Gilead, Janssen, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche and Sanofi; M. M. reports a grant from SIR, honoraria due to advisory boards from Celgene and Sanofi and others from Lilly, Alfa Wassermann, Novartis, Merck Sharp & Dohme outside the submitted work; I. P. reports a grant from SIR; N. U. reports a grant from SIR and honoraria for consultations from Mundipharma Pharmaceuticals outside the submitted work. All other authors have declared no conflicts of interest.

APPENDIX 1
KEYWORDS FOR THE SYSTEMATIC LITERATURE SEARCH

**Medline via Pubmed**

**Embase**

**Grey Literature**
English Grey Literature

Grey Literature Report (http://www.greylit.org) http://www.greylit.org/content/safety-vaccines-used-routine-immunization-united-states


Italian Grey Literature

APPENDIX 2
LEVEL OF AGREEMENT (SCORE 1-10) FOR EACH REVISED RECOMMENDATION RATED BY THE MULTIDISCIPLINARY EXTERNAL COMMISSION (N=10). A MINIMUM SCORE ≥7 WAS USED A PRIORI TO CONSIDER EACH RECOMMENDATION ACCEPTABLE FOR CLINICAL PRACTICE PURPOSES

<table>
<thead>
<tr>
<th>N° Item management</th>
<th>Level of agreement, median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>10 (8-10)</td>
</tr>
<tr>
<td>2</td>
<td>10 (8-10)</td>
</tr>
<tr>
<td>3</td>
<td>9.5 (6-10)</td>
</tr>
<tr>
<td>4</td>
<td>10 (6-10)</td>
</tr>
<tr>
<td>5</td>
<td>8.5 (4-10)</td>
</tr>
<tr>
<td>6</td>
<td>8.5 (7-10)</td>
</tr>
<tr>
<td>7</td>
<td>9 (5-10)</td>
</tr>
<tr>
<td>8</td>
<td>8.5 (5-10)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N° Item management</th>
<th>Level of agreement, median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>8 (3-10)</td>
</tr>
<tr>
<td>2</td>
<td>8 (3-10)</td>
</tr>
<tr>
<td>3</td>
<td>8 (3-10)</td>
</tr>
<tr>
<td>4</td>
<td>8.5 (6-10)</td>
</tr>
<tr>
<td>5</td>
<td>8 (4-10)</td>
</tr>
<tr>
<td>6</td>
<td>9 (5-10)</td>
</tr>
</tbody>
</table>

APPENDIX 3
GLOSSARY AND DEFINITIONS (Adapted from ref 16)

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-dose glucocorticoid</td>
<td>≤7.5 mg/day (prednisone equivalent)</td>
</tr>
<tr>
<td>Tapering</td>
<td>Usually reduction of drug dose or increase of application interval (spacing). May include discontinuation (tapering to 0), but then only after slow reduction.</td>
</tr>
<tr>
<td>Discontinuation</td>
<td>Stopping of a particular drug.</td>
</tr>
<tr>
<td>Cycling (Switch) Strategy</td>
<td>Change drug with the same mode of action in RA patients failing TNF-inhibitors.</td>
</tr>
<tr>
<td>Swapping (Swap) Strategy</td>
<td>Change drug with another mode of action in RA patients failing TNF-inhibitors.</td>
</tr>
<tr>
<td>Synthetic DMARDs</td>
<td>Conventional synthetic DMARDs (csDMARDs): methotrexate, lefluonamide, sulfasalazine, hydroxychloroquine.</td>
</tr>
<tr>
<td>Target synthetic DMARDs (tsDMARDs/JAK-i)</td>
<td>Biologici Originatori/Biosimilari (bDMARDs): abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, sarilumab, tocilizumab.</td>
</tr>
<tr>
<td>Biological DMARDs</td>
<td>Biological Originator/Biosimilar (bDMARDs): abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, sarilumab, tocilizumab.</td>
</tr>
</tbody>
</table>

RA, rheumatoid arthritis; csDMARD, conventional synthetic disease-modifying antirheumatic drug; bDMARD, biologic disease-modifying antirheumatic drug; tsDMARD, target synthetic disease-modifying antirheumatic drug; TNF-inhibitor, tumor necrosis factor inhibitor; JAK-i, janus kinase inhibitor.
■ BIBLIOGRAFÍA

27. Choi HK, Hernán MA, Seeger JD, et al. Me-
47. Torrente-Segarra V, Acosta Pereira A, Morla R, et al. VARIAR study: assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antago-


115. Innala L, Möller B, Ljung L, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk fac-
The Italian Society for Rheumatology clinical practice guidelines for rheumatoid arthritis


139. Kapetanovic MC, Roseman C, Jonsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumo-
149. CIMZIA® Riassunto delle Caratteristiche di Prodotto (agg.19/07/2018).


